Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305795 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
A Phase 1 study of Metastatic Head-and-neck Squamous-cell Carcinoma and Recurrent Head and Neck Squamous Cell Carcinoma, sponsored by Rakuten Medical.
- Active
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 7
- Study locations
NCT04305795 is a Phase 1 study of Metastatic Head-and-neck Squamous-cell Carcinoma and Recurrent Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by Rakuten Medical. The registered enrollment target is 23 participants, below the 126-participant average among 24 other Metastatic Head-and-neck Squamous-cell Carcinoma trials with a reported enrollment target (82% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT04305795, a Phase 1 study of Metastatic Head-and-neck Squamous-cell Carcinoma and Recurrent Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Rakuten Medical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 7
- Study locations
Study Summary
Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
Conditions Studied
Interventions
- BIOLOGICAL 200 mg Pembrolizumab
- BIOLOGICAL 350 mg Cemiplimab
- COMBINATION_PRODUCT ASP-1929 PIT
Study Locations (7)
Florida
- University of Miami Hospital and Clinics - Miami
Kentucky
- University of Kentucky - Lexington
Minnesota
- Mayo Clinic - Rochester
Oregon
- Providence Medical Center - Portland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04305795
The ClinicalTrials.gov registry entry for NCT04305795 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 24 other Metastatic Head-and-neck Squamous-cell Carcinoma trials with a reported enrollment target (82% lower). The listed sponsor is Rakuten Medical, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Metastatic Head-and-neck Squamous-cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which 200 mg Pembrolizumab is the first listed.
NCT04305795 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Florida, Kentucky, Minnesota.
Frequently Asked Questions
What is clinical trial NCT04305795 about?
NCT04305795 is a clinical study titled "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors". Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
What is the current status of trial NCT04305795?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2020-12-21. Estimated completion is 2027-06.
What conditions does trial NCT04305795 study?
This clinical trial studies the following conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04305795?
The interventions under investigation include: 200 mg Pembrolizumab (BIOLOGICAL), 350 mg Cemiplimab (BIOLOGICAL), ASP-1929 PIT (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04305795?
This trial is sponsored by Rakuten Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305795 being conducted?
This trial has 7 study locations across Florida, Kentucky, Minnesota, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Head-and-neck Squamous-cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
RECRUITING · Phase 1
-
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
RECRUITING · Phase 1
-
(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
RECRUITING · Phase 1
-
Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma
RECRUITING · Phase 1
-
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RECRUITING · Phase 1
-
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Head-and-neck Squamous-cell Carcinoma
All registered trials for this condition
Recurrent Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.